Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Mirum Pharmaceuticals Q2 EPS $(0.12) Beats $(0.34) Estimate, Sales $127.785M Beat $107.908M Estimate

Author: Benzinga Newsdesk | August 06, 2025 03:02pm
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.34) by 64.5 percent. This is a 76.92 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $127.785 million which beat the analyst consensus estimate of $107.908 million by 18.42 percent. This is a 64.09 percent increase over sales of $77.875 million the same period last year.

Posted In: MIRM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist